Literature DB >> 9009995

Inclusion body myositis in HIV-1 and HTLV-1 infected patients.

E J Cupler1, M Leon-Monzon, J Miller, C Semino-Mora, T L Anderson, M C Dalakas.   

Abstract

Sporadic inclusion body myositis (IBM) is the most common inflammatory myopathy affecting patients over the age of 50 years. Dysimmune and degenerative aetiologies have been postulated, but viral infections have not been associated with the disease. Two HIV-I (human immunodeficiency virus type 1) infected men and one woman infected with HTLV-1 (human T cell leukaemia virus type 1) developed progressive proximal muscle weakness unrelated to antiretroviral therapy. Their muscle biopsies were studied by light and electron microscopy, by immunocytochemistry to determine the expression of major histocompatibility complex (MHC) molecules and identify the type of infiltrating cells and T cell receptor (TCR) subunits, and by reverse transcription-polymerase chain reaction (RT-PCR) and single or double immunocytochemistry to search for retrovirally infected endomysial cells. The clinical features were consistent with sporadic IBM. The muscle biopsies showed primary endomysial inflammation, red-rimmed vacuoles, amyloid deposits, eosinophilic inclusions, and small round fibres in groups, all diagnostic of IBM. The muscle fibres expressed MHC class-1 antigens and were invaded primarily by CD8+ T-lymphocytes preferentially bearing TCR V beta 5.1 and V beta 13 chains. The HIV-1 or HTLV-1 antigens were detected only on endomysial macrophages on or around muscle fibres, but not within the muscle fibres. We conclude that IBM occurs in HIV-1 and HTLV-1 infected individuals and has a clinical, histological and immunological pattern identical to sporadic IBM in the non-retrovirally infected patients. Retroviruses do not directly infect the muscle, but persistent retroviral infections may provide superantigenic stimulation and trigger an endomysial inflammatory response identical to that occurring in sporadic IBM.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9009995     DOI: 10.1093/brain/119.6.1887

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  16 in total

Review 1.  Neuroimmunity of HTLV-I Infection.

Authors:  Eiji Matsuura; Yoshihisa Yamano; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2010-05-02       Impact factor: 4.147

Review 2.  Immunotherapeutic relief from persistent infections and amyloid disorders.

Authors:  Dorian B McGavern
Journal:  Neurology       Date:  2006-01-24       Impact factor: 9.910

Review 3.  Advances in the immunobiology and treatment of inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

Review 4.  Inclusion Body Myositis: Update on Pathogenesis and Treatment.

Authors:  Elie Naddaf; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

5.  Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement.

Authors:  N A Goyal; T M Cash; U Alam; S Enam; P Tierney; N Araujo; F H Mozaffar; A Pestronk; T Mozaffar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-04-09       Impact factor: 10.154

6.  Muscle wasting induced by HTLV-1 tax-1 protein: an in vitro and in vivo study.

Authors:  Simona Ozden; Vincent Mouly; Marie-Christine Prevost; Antoine Gessain; Gillian Butler-Browne; Pierre-Emmanuel Ceccaldi
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

7.  Direct evidence for a chronic CD8+-T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type 1-infected patient with sporadic inclusion body myositis.

Authors:  Simona Ozden; Madeleine Cochet; Jacqueline Mikol; Antonio Teixeira; Antoine Gessain; Claudine Pique
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 8.  Newest pathogenetic considerations in inclusion-body myositis: possible role of amyloid-beta, cholesterol, relation to aging and to Alzheimer's disease.

Authors:  Valerie Askanas; W King Engel
Journal:  Curr Rheumatol Rep       Date:  2002-10       Impact factor: 4.592

9.  How citation distortions create unfounded authority: analysis of a citation network.

Authors:  Steven A Greenberg
Journal:  BMJ       Date:  2009-07-20

10.  Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients.

Authors:  Thomas E Lloyd; Iago Pinal-Fernandez; E Harlan Michelle; Lisa Christopher-Stine; Katherine Pak; Ned Sacktor; Andrew L Mammen
Journal:  Neurology       Date:  2017-03-10       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.